Literature DB >> 14996229

Pharmacologic management part 2: lesser-studied neuropathic pain diseases.

Misha-Miroslav Backonja1, Jordi Serra.   

Abstract

This second part of a review of the pharmacologic management of neuropathic pain diseases describes the current treatment options for three lesser-studied neuropathic syndromes: Central poststroke pain, spinal cord injury, and complex regional pain syndrome II. Diagnosis can be difficult in patients with these syndromes, because the pain experienced is much greater and of a different type than would normally be expected following a stroke or injury to the spinal cord or a peripheral nerve. Even when an accurate and timely diagnosis is made, treatment options are limited and frequently suboptimal. However, the results of published trials do support the use of anticonvulsants and/or tricyclic antidepressants as first-line pharmacotherapy in these three neuropathic pain syndromes. To maximize treatment outcomes, future research must: Continue to more fully elucidate the relationship between the signs and symptoms of pain and the underlying pathophysiology; Delineate the natural history of central poststroke pain, spinal cord injury, and complex regional pain syndrome; Identify patient-related factors that may indicate an increased risk of developing neuropathic pain following stroke or nerve injury; Investigate emerging treatments that target underlying pain mechanisms. Copyright American Academy of Pain Medicine

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996229     DOI: 10.1111/j.1526-4637.2004.04021.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  4 in total

Review 1.  Central poststroke pain: an abstruse outcome.

Authors:  James L Henry; Chitra Lalloo; Kiran Yashpal
Journal:  Pain Res Manag       Date:  2008 Jan-Feb       Impact factor: 3.037

Review 2.  The Management of Poststroke Thalamic Pain: Update in Clinical Practice.

Authors:  Songjin Ri
Journal:  Diagnostics (Basel)       Date:  2022-06-10

3.  Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting.

Authors:  Emilio Blanco Tarrio; Rafael Gálvez Mateos; Enric Zamorano Bayarri; Vanessa López Gómez; Maria Pérez Páramo
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

4.  Therapeutic effects of thymoquinone in a model of neuropathic pain.

Authors:  Feyzi Celik; Cüneyt Göçmez; Haktan Karaman; Kağan Kamaşak; Ibrahim Kaplan; Eşref Akıl; Adnan Tufek; Abdulmenap Guzel; Ertuğrul Uzar
Journal:  Curr Ther Res Clin Exp       Date:  2014-01-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.